Cataract lasers mkt. to hit $2.4 B by 2019, study forecasts

Article

The worldwide market for cataract surgery lasers is forecast to exceed $2.4 billion by 2019, according to a recent study conducted by WinterGreen Research Inc.

Lexington, MA-The worldwide market for cataract surgery lasers is forecast to exceed $2.4 billion by 2019, according to a recent study conducted by WinterGreen Research Inc.

WinterGreen’s published report, Femtosecond Lasers for Cataract Surgery Market Shares, Strategies, and Forecasts, Worldwide, 2013-2018, details how femtosecond laser technology represents a paradigm shift in treating patients with cataracts. The study attributes the driving force behind femtosecond lasers’ market dominance to the ever-increasing aging baby boom population.

Because of the simultaneous change in demographics and the introduction of automated cataract surgery, eyecare professionals face an explosion in demand for their services over the next 20 years. The aging baby boomers and the fact that patients older than 65 consume 10 times the eye care of patients younger than 65 creates unprecedented demand for cataract surgery.

As a result, growing needs and expectations for good vision in all ranges have created significant new market opportunities, expanding demand for multifocal and accommodating IOLs designed to correct presbyopia, aspheric optics that address spherical aberration and make vision sharper, and phakic IOLs allowing treatment of extreme refractive error.

“Superior image quality brings clinical improvement. Patients are thrilled when they can see so much more clearly,” said Susan Eustis, president and co-founder of WinterGreen Research, and lead author of the research team.

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.